10.54 +0.02 (0.19%)
After hours: 6:30PM EST
|Bid||10.48 x 2900|
|Ask||10.54 x 800|
|Day's range||10.20 - 10.77|
|52-week range||6.25 - 13.30|
|Beta (5Y monthly)||1.45|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||27 Nov 2017|
|1y target est||12.66|
For more than a decade, growth stocks have left value stocks eating their dust. Historically low lending rates and a record-long bull-market run have wet the appetites of investors looking for game-changing growth stocks. What's more, value stocks have historically outperformed during the early years of an economic recovery.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Executive Vice President & CFO Eli Kalif will present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference on Tuesday, March 2, 2021 at 8:30 a.m. Eastern Time.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) highlights results from the in vitro study "Migraine Therapeutics Differentially Modulate the CGRP Pathway," which were published online by Cephalalgia, a monthly journal published on behalf of the International Headache Society. These results will also be featured in a future print issue of the journal. This study demonstrated marked differences in the mechanism of blocking the calcitonin gene-related peptide (CGRP) ligand versus the CGRP receptor.